Trial of Sodium Valproate in Amyotrophic Lateral Sclerosis

Phase 3 Completed 165 enrolled UMC Utrecht Princess Beatrix Muscle Foundation · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether the use of sodium valproate is effective in slowing the disease progression in Amyotrophic Lateral Sclerosis.

Timeline

Start: 2005-04
Primary completion: —
Completion: 2007-02

Outcome

Missed primary endpoint

paper VPA did not affect survival PMID 19743466 ↗

paper Our finding that VPA, at a dose used in epilepsy, does not show a beneficial effect on survival PMID 19743466 ↗

Publications

Piepers S, Veldink JH, de Jong SW, van der Tweel I, van der Pol WL, Uijtendaal EV, Schelhaas HJ, Scheffer H, de Visser M, de Jong JM, Wokke JH, Groeneveld GJ, van den Berg LH. Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. Ann Neurol. 2009 Aug;66(2):227-34. doi: 10.1002/ana.21620.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Valproate	Small molecule	1500 mg	—